
Opinion|Videos|April 4, 2025
C-Peptide and Early Type 1 Diabetes Detection
A panelist discusses how C-peptide serves as a critical biomarker of endogenous insulin production, providing clinicians with valuable insights into remaining beta cell function that can guide personalized treatment approaches and help predict disease progression in patients with type 1 diabetes (T1D).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- C-peptide is increasingly recognized as a marker for beta cell function. Can you explain the role of C-peptide in practice?
- How does early identification of T1D change the trajectory of disease management?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























